



GLIMEPIRIDE FAST DISINTEGRATING TABLETS: FORMULATION, EVALUATION AND IN VIVO 
DISINTEGRATION AND DYNAMIC STUDIES 
Original Article 
 
SATHEESH JOGALA*1, LAXMAN ANKATHI2, RAMESH NAIK JARUPULA2,3 
1Department of Pharmaceutics, Mother Teresa College of Pharmacy, NFC Nagar, Ghatkesar, Hyderabad 501301, 2Aurobindo College of 
Pharmaceutical Sciences, Gangadevipally, Narsampet, 3St. Peters Institute of Phamraceutical Sciences,vidya Nagar, Hanamkonda 
Email: sateesh.jogala@gmail.com    
 Received: 08 Feb 2016 Revised and Accepted: 30 Mar 2016 
ABSTRACT  
Objective: The main objective of the research was to formulate directly compressible fast disintegrating tablets of glimepiride by using different 
super disintegrants such as crospovidone, croscarmellose sodium, sodium starch glycolate and L-HPC in various concentrations.  
Methods: The prepared tablets were evaluated for various tablet properties like weight variation, thickness, hardness, friability, taste, drug content, 
in vitro and in vivo disintegration time, and in vitro drug release, in vivo dynamic studies. Other parameters such as wetting time, water absorption 
ratio, and drug-excipient compatibility were also evaluated.  
Results: The disintegration time of the optimized fast disintegrating tablet formulation was observed to be 12 s in vitro and 19.80 s in vivo. The 
correlation was observed between disintegration time and ‘R’ for each of the four super disintegrants at the concentrations studied. Considering the 
‘R’ values and disintegration time, croscarmellose sodium was significantly superior compared to the other super disintegrants tested. Drug release 
was faster from formulations containing 25% croscarmellose sodium compared to the pure drug and without super disintegrant glimepiride tablet. 
FTIR studies did not indicate any excipient incompatibility, either during mixing or after compression. Optimized formulation exhibited good results 
in the decrease in blood glucose in rats when compared to the pure drug and marketed product.  
Conclusion: Form the results if this study it can be concluded that prepared optimized fast disintegrating tablets of glimepiride are the better 
option to treat diabetes. 
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INTRODUCTION 
The elderly constitute a major portion of today’s population mainly 
because of increased life span of individuals. Physiological and 
neurological conditions, such as dysphasia, a risk of choking, and 
hand tremors are leading causes of patient non-compliance in the 
self-administration of conventional solid oral dosage forms [1]. 
Because of impaired swallowing ability, many elderly patients find it 
difficult to take some conventional dosage forms such as tablets and 
capsules. In order to overcome this problem, the development of 
solid dosage forms that disintegrate fast or dissolve even when 
taken orally without water is being undertaken, as well as travelling 
patients who may not have ready access to water and suitability for 
geriatric and pediatric patients and patients suffering from nausea, 
vomiting, those with mental disorders, the bedridden patients [2-4]. 
Many attempts having fast disintegrating behavior have been 
reported like lyophilizing, molding and compressing wet powders to 
construct highly porous structure. However, these methods require 
particular machines and are time-consuming techniques; moreover, 
the hardness of the products was not enough to stand the process of 
packaging and transportation. Therefore, direct compression is the 
simplest, most convenient and easiest way to produce fast 
disintegrating tablets with sufficient structural Integrity [5]. 
The technologies utilized for the manufacturing of FDTs have been 
reported. These includes vacuum drying, lyophilizing, molding and 
compressing wet powder to construct the highly porous structure, 
crystalline transition method, wet granulation method, and direct 
compression method, nanonization, mass extrusion, quick dissolve 
film [2, 6]. But these methods required the particular machines and 
the time-consuming techniques; the hardness of the products was 
not enough to stand up to the process of packaging and 
transportation. In order to overcome these problems direct 
compression is a convenient and cheap way to produce tablets with 
sufficient structural integrity [4]. 
The important factors for the fast disintegrating tablets (FDTs) are fast 
absorption or wetting of water into the tablets and disintegration of 
associated particles into individual components for fast dissolution so 
that it can be absorbed. Fast disintegrating tablets constitute several 
excipients are involved in a complex series of dissolution that begins 
when the solvent contacts the solid and penetrates the tablet matrix 
[4, 5]. This requires not only that excipients should have high 
wettability, but also that the tablet structure should have a highly 
porous network. When conventional direct compression and 
granulation methods are employed, the porosity of the tablets is 
inversely related to the compression pressure. However, high 
compression pressure is needed to ensure adequate strength of the 
tablets. Thus, it is often difficult for the tablet to have porosity that 
allows fast water absorption while maintaining high mechanical 
strength. New strategies to increase tablet the porosity without 
sacrificing its mechanical performance are desired [7]. 
FDTs are also known as fast disintegrating, fast dispersing, rapid 
dissolving, and rapid melting, and or orodisperse tablets. The 
European Pharmacopoeia defines the term orodisperse as a tablet 
that can be placed in the mouth where it disperses or disintegrates 
fastly before swallowing [1, 8]. 
FDTs approved by United States Food and Drug Administration are 
classified as fast disintegrating tablets. The advantages of this 
dosage form over conventional tablets or capsules include ease of 
administration, patient compliance, and palatability. The fast 
disintegration of tablets inside the mouth renders possibly a certain 
degree of absorption throughout the buccal mucosa or the 
sublingual. The drug candidates that undergo pre-gastric absorption 
when formulated as FDTs may show increased dissolution. From the 
perspective of the pharmaceutical industry, FDTs may provide new 
business opportunities in the form of product differentiation, line 
extension and life cycle management, exclusivity, uniqueness, and 
patent life extension. The significant limitation of FDT formulations 
is product cost since manufacturing involves use of novel excipients 
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and technologies. In addition, the specialized packaging is necessary 
to withstand handling and transportation mechanics [1, 9]. 
The saliva plays an important role in the disintegration of FDTs and 
primarily secreted in the oral cavity by parotid, submandibular 
(submaxillary), sublingual glands, and also by numerous minor glands. 
Saliva is mainly composed of water (99.5% w/v) and the remaining 
0.5 % w/v is constituted by dissolved compounds. The important 
components of saliva are inorganic electrolytes (0.2% w/v), gasses 
(CO2, N2, and O2), nitrogen products, such as urea and ammonia, 
vitamin C, creatinine, and mucins (glycoprotein with high molecular 
weight which renders the saliva viscous and adhesive). The accepted 
range of normal salivary flow is comprised from about 0.1 to 0.2 
ml/min and reaches 7 ml/min upon stimulation [1, 9]. 
Glimepiride, 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxami -
do) ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl) urea, is a 
new oral sulfonylurea hypoglycemic agent for the treatment of non-
insulin dependent (type II) diabetes mellitus. 
It causes hypoglycemia by stimulating the release of insulin from 
pancreatic β cells and by increasing the sensitivity of the 
peripheral tissue to insulin. It also promotes the movement of sugar 
from the blood into the cells that need it. Glimepiride is practically 
insoluble in water (2.7 × 10−4 mg/ml at 25 °C) and belongs to “Class 
II” drugs in the Biopharmaceutical Classification System. It is likely 
to display low and irregular bioavailability following oral 
administration due to the low solubility [7]. 
In the present study our goal was to develop directly compressible 
fast disintegrating tablets of glimepiride by using different super 
disintegrants such as crospovidone, croscarmellose sodium, sodium 
starch glycolate and L-HPC in various concentrations and evaluate 
various tablet properties like weight variation, thickness, hardness, 
friability, taste, drug content, in vitro and in vivo disintegration time, 
and in vitro drug release, in vivo dynamic studies. Further, other 
parameters such as wetting time, water absorption ratio, and drug-
excipient compatibility were also evaluated and the results were 
discussed. 
MATERIALS AND METHODS 
Materials 
Glimepiride, Crospovidone(CP), Croscarmellose sodium(Ac-Di-
Sol,CCS), Primogel (Sodium starch glycolate,SSG), Low-substituted 
hydroxyl propyl cellulose (L-HPC). 
Microcrystalline cellulose (Avicel pH 102); Magnesium stearate; and 
colloidal silicon dioxide (Aerosil) were purchased from Qualikems fine 
chemicals; Streptozotocin was purchased from Himedia chemicals 
(Mumbai, India). All chemicals used in the study were of analytical grade. 
Methods 
Assignment of formulation codes 
Various formulations of glimepiride fast disintegrating tablets 
(FDTs) were designed utilizing four super disintegrants, 
crospovidone (CP), croscarmellose sodium (CCS), sodium starch 
glycolate (SSG) and low-substituted hydroxyl propyl cellulose (L-
HPC) each varied at different levels of concentration. All of the other 
ingredients were kept constant except diluents concentration varied. 
A total of such fourteen formulations prepared were designated with 
their codes and will be referred to the same in further sections. The 
assigned formulation codes were as follows: F1, F2, F3, F4, F5, F6, 
F7, F8, F9, F10, F11, F12, F13 and F14 for formulations containing 
CP as the super disintegrant with concentrations of 5,10 and 15%, 
respectively. Similarly, CCS 5,10, 15, 20, 25 %, and SSG 5, 10, 15 % 
and L-HPC 5,10,15 % were the assigned codes for the formulations 
prepared with these respective super disintegrants at the 
percentage levels provided for above super disintegrants.  
Preparation of glimepiride fast disintegrating tablets  
Glimepiride fast disintegrating tablets were prepared by direct 
compression technique [5-7]. Each tablet was composed of 5 mg 
glimepiride, 1 mg of magnesium stearate as a lubricant, 0.5 mg 
colloidal silicon dioxide as a glidant, 0.5 mg orange flavor and 
various concentrations of the excipients as follows: either Ac-Di-Sol, 
Primojel or L-HPC and crospovidone as disintegrants; Avicel PH102 
as diluents to complete the final weight of the tablet to 100 mg. Before 
compression, the previously sieved drug, diluent, glidant, and 
disintegrant were mixed in a glass mortar; then the lubricant was 
added, and mixing was continued for further 5 min. One hundred 
milligrams of powder mixture was manually filled into the 7 mm die 
and compressed into flat-faced tablets at hardness ranging from 2-4 
kg/cm2 using a 16-station single rotary tablet machine. Table. 1 shows 
the outlines of the compositions of various FDT formulations studied. 
Evaluation of prepared glimepiride FDTs 
Weight variation 
Twenty tablets from each formula were randomly selected and was 
weighed individually using an electronic (Shimadzu, AUX 220, 
Japan) digital balance and mean of tablet weights was calculated. 
Results are presented as mean±standard deviation (SD).  
Thickness variation 
From all the prepared formulations, ten tablets from each 
formulation were taken randomly, and their thickness was 
measured with a digital vernier caliper (Mitutoyo Corp, Kawasaki, 
Japan). The mean±SD values were calculated. It should be controlled 
within±5 % variation of standard value. 
Hardness and friability 
Hardness or crushing strength of the tested FDT formulations was 
measured using the Monsanto hardness tester. The friability of a 
sample of 10 FDTs was measured utilizing a USP-type Roche 
friabilator (TA-024, Inco instruments& chemical ltd). Pre-weighed 
tablets were placed in a plastic chambered friabilator attached to a 
motor revolving at a speed of 25 rpm for 4 min. The tablets were 
then de-dusted, accurately reweighed, and percentage loss in weight 
(friability) was calculated. 
Content uniformity 
The FDT formulations were assayed for drug content. 
Ten glimepiride tablets were randomly selected from each 
formulation (containing 5 mg glimepiride) were weighed and 
pulverized to a fine powder in the mortar. The average weight of a 
tablet was calculated. A sufficient quantity equivalent to the average 
weight of tablet content was accurately weighed from the tablet 
powder and methanol was added to dissolve the active material and 
made up to the volume of 100 ml in a volumetric flask [12]. Then 1 
ml of this solution was taken and put into another volumetric flask. 
Then it was completed to 25 ml with phosphate buffer pH 7.8. It was 
centrifuged for 10 min and supernatant was filtered through a 0.22 
µm filter, and resulted supernatant solution absorbance value at 228 
nm was determined using Systronics UV–Vis spectrophotometer 
2202-India, and with the aid of the calibration equation drug amount 
in the sample was calculated. 
Wetting time 
The tissue papers were placed in a petri dish by folding it into five 
circular form in a 10 cm diameter. Petri dish containing ten milliliters 
of water with 0.5 % nigrosine, a water-soluble dye, was added to the 
petri dish. The dye solution was used to identify complete wetting of 
the tablet surface. The Tablet was carefully placed on the surface of the 
tissue paper in the center of the petri dish at 25 °C. The time required 
for water to reach the upper surface of the tablets and to completely 
wet them was noted as the wetting time [1,3,14]. These measurements 
were carried out in replicates of six. Wetting time was recorded using 
a stopwatch and presented as mean±SD. 
Water absorption ratio (R) 
The weight of the tablet prior to placement in the petri dish was 
noted (wb) utilizing a Shimadzu digital balance. The wetted tablet 
was removed and reweighed (wa). Water absorption ratio, R, was 
then determined according to the following equation. 
R=100×(wa-wb)/wb 
Where wb and wa were tablet weights before and after water 
absorption, respectively. 
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In vitro disintegration time 
The disintegration of tablets was determined using a USP 
disintegration testing apparatus type II (Paddle, Electrolab ED-2L, 
India) with pH 6.8 phosphate buffer as a disintegrating medium. The 
medium was maintained at 37±0.5 °C throughout the test. Six tablets 
were placed into an apparatus and disintegration time was recorded 
[16]. Measurements were carried out in replicates (n=6) and 
mean±SD values were recorded. 
In vitro dissolution studies 
The drug release was determined using USP standard dissolution 
tester, Apparatus II rotating paddle (Electrolab TDT-08L, India). 
Dissolution was carried out in 300 ml of phosphate buffer at pH 7.8. 
The paddle was rotated at 75 rpm at 37±0.5ºC. Aliquots of 5 ml were 
withdrawn and replaced with equal volumes of fresh phosphate 
buffer pH 7.8 at specified time intervals (5, 10, 15, 20, 30, 40, 50 and 
60 min). Samples were adequately diluted, filtered through a 0.22 
µm filter and analyzed with spectrophotometrically for their 
glimepiride in phosphate buffer pH 7.8 at 228 nm (Systronics UV–Vis 
spectrophotometer 2202-India). Drug concentration was calculated 
from a standard calibration plot and expressed as cumulative % 
drug dissolved. The experiments were done in triplicates (n=3) for 
each of the selected FDT formulae. 
In vivo oral disintegration time 
The disintegration time of FDTs is measured utilizing the 
conventional tests for tablets that are described in the 
Pharmacopoeias. It is very difficult to assess the disintegration rate 
for the FDT with these tests due to its rapid disintegration rate even 
in a small amount of water. So, the disintegration rate obtained from 
the conventional disintegration tests appears not to be reflective of 
the disintegration rate in the human mouth. Because of this standard 
compendia test faces many disadvantages in the discrimination 
between different FDTs as their disintegration time is very short and 
also because of the strong agitation and large volume of water used 
during this test [24]. The measurements of disintegration time in the 
oral cavity were carried out in six healthy volunteers (mean age = 
23.5±1.04 y). Prior to the test, all volunteers got a detailed briefing 
on purpose and protocol of this test. The institutional ethics 
committee approved the in the vivo study protocol, and each subject 
gave his written consent to participate. As per the protocol. Then 
they were asked to rinse their mouth with a cup of water (200 ml). 
The FDT was placed on the subject’s tongue and immediately a 
stopwatch was started as soon as the tablet contacts the tongue. The 
subjects were instructed to move gently the tablet against the upper 
part of the mouth with their tongue and to cause a gentle tumbling 
action on the tablet [4, 17, 20]. It was emphasized to the subjects 
that this is a gentle motion without biting on the tablet or tumbling it 
from side to side. Immediately after the last noticeable granule had 
disintegrated, the time was recorded. The swallowing of saliva was 
prohibited during the test, and also, saliva was rinsed from the 
mouth after each measurement [15-18, 24]. 
In vivo pharmacodynamic studies 
Prepared glimepiride tablets were administered to male 
albino Wister rats to investigate the biological activity of new 
prepared optimized glimepiride tablet in comparison with the 
directly compressed tablet and pure drug. 
Experimental design 
Rats were divided into the following groups. 
Group I: (Control group) consisted of 6 rats which served as control 
Group II: (DCT group) consisted of rats they will be with the oral 
dose of the directly compressed tablet that is without super 
disintegrant (DCT). 
Group III: (Pure drug): Consisted of 6 rats and they will be with the 
oral dose of the pure drug (Glimepiride). 
Group IV: (Glimepiride formula group) consisted of 6 rats and they 
will be with the oral dose of glimepiride optimized tablet. 
Preparation of reagents 
Preparation of citrate buffer 
0.1 M citrate buffer was prepared by dissolving 1.47 g of sodium 
citrate in 50 ml of deionized water; adjust the pH to 4.5 by using 
monohydrate citric acid solution. 
Preparation of streptozotocin solution 
Streptozotocin was prepared by dissolving required amount of 
Streptozotocin (it is calculated according to the body weight of 
individual rat) in required amount of citrate buffer. 
Preparation of glucose solution 
5% glucose was prepared by dissolving 5 g of glucose dissolved in 
100 ml distilled water. 
Induction of diabetes 
Prior to the induction of diabetes, all the male albino rats of Wistar 
strain (150-250 g; 4-6 w old) were maintained under controlled 
conditions of light (12 h/24 h) and temperature (23±1ºC). The 
animals were fasted for overnight. A single dose of streptozotocin 
(40 mg/kg) was administered through intraperitoneal route to the 
Groups II, III and IV rats. While normal control rats were injected 
with buffer alone. Streptozotocin was dissolved in freshly prepared 
0.1M citrate buffer pH (4.5). Streptozotocin injected animals were 
given 5 % glucose for 24 h to prevent initial streptozotocin-induced 
hypoglycemic mortality [15, 19]. 
Blood sampling 
Blood samples were withdrawn from the animals after 
predetermined intervals 15 min, 30 min, 45 min, 60 min, 2 h, 4 h, 6 
h, 8 h, 12 h, 24 h through the tail vein. 
- 
Table 1: Composition of Glimepiride fast disintegrating tablets 




















F1  5 5    87  1 1 0.5 0.5 
F2 5 10    82  1 1 0.5 0.5 
F3 5 15    77  1 1 0.5 0.5 
F4  5 - 5   87  1 1 0.5 0.5 
F5  5 - 10   82  1 1 0.5 0.5 
F6  5 - 15   77  1 1 0.5 0.5 
F7 5 - - 5  87  1 1 0.5 0.5 
F8  5 - - 10  82  1 1 0.5 0.5 
F9  5 - - 15  77  1 1 0.5 0.5 
F10  5 - - 20  72  1 1 0.5 0.5 
F11 5 - - 25  67  1 1 0.5 0.5 
F12  5 - - - 5 87  1 1 0.5 0.5 
F13  5 - - - 10 82  1 1 0.5 0.5 
F14  5 - - - 15 77  1 1 0.5 0.5 
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Determination of blood glucose levels 
Blood glucose levels were determined using a glucometer. The blood 
samples were withdrawn for determination of blood sugar after 15 
min, 30 min, 45 min, 60 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h. The blood 
sugar levels were then plotted against time. 
Fourier transforms infrared spectroscopy (FTIR) 
Drug excipient incompatibility was studied by Fourier transform 
infrared spectroscopy. FTIR studies were performed on drug, 
Croscarmellose sodium, physical mixture and the optimized 
formulated compressed tablet using Shimadzu IR Prestige FTIR 
Spectrophotometer Prestige, India. The samples were analyzed for 
wave numbers 4000 and 400 cm. 
RESULTS AND DISCUSSION 
Formulation rationale 
The objective of a directly compressible fast disintegrating tablet is 
that it disintegrates or disperses in the saliva within a matter of 
seconds. The super disintegrants form the core of FDT formulations. 
Crospovidone (CP), croscarmellose sodium (CCS), sodium starch 
glycolate (SSG) and Low-substituted hydroxyl propyl cellulose (L-
HPC) are four of the most commonly used and highly effective super 
disintegrants currently included in solid dosage formulations. In this 
study, CP, CCS, SSG and L-HPC in the glimepiride FDT formulations 
was evaluated at different concentrations. Other formulation 
components were kept constant except diluent concentration. 
CP polymers are densely cross-linked homopolymers of N-vinyl 2-
pyrrolidones. CP rapidly absorbs liquids into the tablet by capillary 
action and to generate rapid volume expansion and hydrostatic 
pressures that result in tablet disintegration due to their porous 
particle morphology. One researcher in his research study reported, 
in addition, to its unique particle size and morphology, disintegrant 
properties of CP are not affected by pH and consequently being non-
ionic does not bind to ionic drug moieties, it can also be used as a 
solubility enhancer to improve dissolution and, unlike other super 
disintegrants, does not form a gel at higher concentrations [1]. 
CCS is cross-linked carboxymethyl cellulose sodium; Its unique 
fibrous nature imparts excellent water-wicking properties and 
cross-linking makes it a hydrophilic and highly absorbent material 
resulting in excellent swelling properties. CCS swells rapidly up to 4–
8 times its original volume in contact with water. Similar to CP, it is 
also used as a dissolution aid. 
SSG, a sodium salt of carboxymethyl ether of starch. Disintegration 
occurs as a result of rapid uptake of water followed by rapid and 
enormous swelling, which is its primary mechanism of action [1, 12, 
13]. SSG may swell up to 300 times its original volume in water. 
L-HPC (Low-substituted hydroxypropyl cellulose) is partially 
substituted hydroxypropyl ether of cellulose in which a small 
proportion of the three hydroxyl groups contained in the β-o-
glucopyranosyl ring of the cellulose is etherified with propylene 
oxide. While highly substituted hydroxypropyl ether of cellulose is 
soluble in both water and alcohols, L-HPC is insoluble in these 
solvents, but it swells in water. Different grades are available that 
differ in hydroxyl propyl content and in particle size [21, 22]. 
Avicel PH102 was included in the formulation as a disintegrant and a 
diluent. This grade of microcrystalline cellulose is powder in nature 
and commonly used direct compression filler. Owing to excellent 
compressibility, it is widely added in tablet formulations to improve 
hardness and prevent capping. 
Colloidal silicon dioxide (Aerosil®), which acts both as a glidant and 
lubricant, also helps in appreciably decreasing tablet friability. This 
may be due to Aerosil® helping in restoring the bonding properties 
of the excipients. 
Evaluation of the prepared glimepiride FDTs 
All the glimepiride tablet formulations containing these four super 
disintegrants at different concentrations were evaluated. Weight 
variation and thickness are within mean±7.5 % and mean±5 %, 
respectively. FDT should disintegrate rapidly upon placement in the 
mouth, yet possess sufficient structural integrity to withstand handling 
without substantial breakage. Thus, tablet properties such as hardness, 
and friability are closely linked to causing rapid tablet disintegration.  
The hardness of all the prepared tablets was in the range of 2.3±2.9 
kg/cm2 for all the fast disintegrating tablets.  
The friability is a measurement of the tablet’s physical strength. It 
was stated that an acceptable friability for dispersible tablets ranges 
from 0.52 % to 0.73 %. All the prepared formulation had no tablet 
was cracked, split or broken in either formula.  
Content uniformity was found to be good where the percentage of 
drug content was found to be in the range of 96 % to 98 %. 
Disintegration time is an important criterion for selecting an 
optimum FDT formulation. Several methods have been described for 
evaluating in vitro and in vivo disintegrating time of FDT formulations. 
In vitro disintegrating time was determined following the procedure 
described in a previous section [6, 17]. According to the compendia 
standards, FDT should disintegrate within 3 min when examined by 
the test for the disintegration of tablets and capsules [22]. 
 
Table 2: Evaluation of glimepiride fast disintegrating tablets 
Formulation  Weight variation*  (mg) Thickness** (mm) Hardness** kg/cm2 % Friability** (%) Drug content*** (%) 
F1  95.14±1.21  2.2±0.2  2.5±0.06  0.52±0.12 96±0.7  
F2  98.97±1.14  2.21±0.14  2.3±0.08  0.68±0.20 97.2±0.4  
F3  99.73±0.87  2.1±0.12  2.4±0.2  0.72±0.15 95.8±0.56  
F4  96.10±0.87  2.2±0.08  2.6±0.18  0.59±0.12 97.4±0.8  
F5  101.01±0.96  2.4±0.13  2.4±0.1  0.73±0.14 97.8±0.3  
F6  99.16±0.9  2.3±0.18  2.6±0.12  0.67±0.17 98±0.27  
F7  96.9±0.7  2.2±0.2  2.8±0.1  0.55±0.12 96.8±0.8  
F8  98.4±1.1  2.1±0.1  2.2±0.2  0.54±0.09 95.8±0.55  
F9  98.1±0.97  2.3±0.12  2.6±0.1  0.64±0.13 97.8±0.47  
F10  98.4±1.1  2.2±0.1  2.7±0.13  0.69±0.12 97.8±0.68  
F11  99.75±0.89  2.2±0.18  2.8±0.08  0.72±0.11 98±0.37  
F12  98.4±0.92  2.1±0.2  2.9±0.12  0.58±0.10 96.2±0.43  
F13  99.14±0.99  2.1±0.08  2.5±0.14  0.69±0.11 96.6±0.86  
F14  98.5±0.91  2.2±0.06  2.4±0.2  0.71±0.10 96±0.075  
Results are the mean of 20 observations±SD; **Results are the mean of 10 observations±SD, ***Results are the mean of 3 observations±SD 
 
From the observation the increasing, the super disintegrant 
concentration resulted in a decrease in disintegrating time as 
depicted in fig. 1. The disintegrating time of formulations containing 
CCS were lower than those containing SSG,CP and L-HPC which 
might be attributed due to its rapid water-absorbing nature 
involving both capillary and swelling mechanisms, and delayed 
disintegration time for other super disintegrates due to their 
tendency to gel more than Croscarmellose sodium. 
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Fig. 1: Disintegrating time for various formulations (n=6, mean±SD) 
 
The mechanism involved in Croscarmellose sodium is when it comes 
into contact with water it swells to a large extent to disintegrate the 
tablets. Also, it has fibrous nature that allows intra-particulate as 
well as extra-particulate wicking of water even at low concentration 
levels. In the case of crospovidone has excellent wicking nature and 
pronounced hydration, though it swells only to a small extent with 
little tendency to gel formation, and disintegrate rapidly but into 
larger masses of aggregated particles [2-4]. 
Because disintegration time of tablets contained crospovidone was 
delayed resulting the filling up of tablet porosity with formulating 
magnesium stearate which possessed hydrophobic property. 
Observed results suggested that the disintegrants added into tablet 
formulations might cause the penetration behavior of water in the 
tablet, and the penetration rate of water would be altered [5, 6]. The in 
vitro disintegration time for all formulation was found to be 12-142 s. 
Wetting time and water absorption ratio for the prepared 
glimepiride FDTs 
All the formulations were wetted within an acceptable time of less 
than 1 min, where F4, F5, F6, F7, F8, F9, F10, and F11 were wetted in 
36±0.89, 32.6±1.3, 29.5±1.04, 34.5±1.87, 30.8±1.16, 27±0.89, 
21.5±1.04 and 19.85±0.75 s respectively. However, the longest wetting 
time was taken by F1, F2, F3, F12, F13 and F14 which were 105.3±1.9, 
96.8±1.8, 86±1.4, 187.5±1.04, 160.3±1.6 and147.1±1.16 s, 
respectively. It was also observed that formula F11 which had the least 
wetting time also had the minimum disintegration time showing a 
strong correlation between disintegration times and wetting time. 
 
 
Fig. 2: Wetting time for various formulations (n=6, mean±SD) 
Fig. 2 shows in details the main effects of each additive on the 
tablets’ wetting time. Regarding the effect due to disintegrants (fig. 
3), they can be arranged in ascending order as follows: Ac-Di-
Sol<Primojel<CP<L-HPC with mean wetting time values of 26.7, 
32.7, 96 and 164.9 s, respectively.  
 
 
Fig. 3: Water absorption ratio for various formulations (n=3, 
mean±SD) 
 
From the Fig.3. it was observed that the formulae are containing 
Primojel as disintegrant had higher mean water absorption ratio 
than Ac-Di-Sol, CP and L-HPC, and took more time for wetting of 
tablets than Ac-Di-Sol this high water uptake lead to less patient 
convenience while taking the FDTs. Wetting is closely related to the 
inner structure of the tablets and the hydrophilicity of excipients. 
Primojel shows its disintegration effect by the mechanism of 
‘‘swelling”. Ac-Di-Sol shows its disintegration action by ‘‘wicking” 
(due to its fibrous structure) and swelling with minimum gelling. It 
had the minimum wetting time and the minimum water absorption 
ratio. Increased porosity of Ac-Di-Sol provides pathways for the 
penetration of fluids into tablets resulting in ‘‘wicking” through 
capillary action causing faster disintegration of tablets [1, 18, 24]. 
In vitro dissolution studies 
The drug release time for the crospovidone formulations was found 
at the F1, F2, and F3 are at 10 min (22.47±0.41), (28.34±0.25), and 
(30.62±0.24) respectively. From the above observations, it is 
concluded that F3 formulation gives maximum drug release within 
10 min (fig. 4). 
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Fig. 4: In vitro drug release studies on prepared tablets at 
different concentrations of Crospovidone (n=3, mean±SD) 
 
The maximum drug release time for the sodium starch glycolate 
formulations was found at the F4, F5, and F6 are 5 min 
(29.1±0.32) (37.1±0.48)(48.3±0.48) 60 min (39.33±0.43), 60 
min (45.68±0.32), and 60 min (56.49±0.33) respectively. The 
initial drug release for formulation F4 at 5 min is 29.78±0.32. 
From the above observations, it is concluded that by increasing 
the concentration of Sodium starch glycolate, the drug releases 
at a faster rate (fig. 5). 
 
 
Fig. 5: In vitro release studies of prepared tablets at different 
concentrations of sodium starch glycolate (n=3, mean±SD) 
 
The drug release time for the formulations was found at the F7, F8, 
F9, F10, and F11 are at 10 min (44.90±0.16), 10 min (50.19±0.32), 
10 min (62.96±0.32), 10 min (70.17±0.33) and 10 min 
(84.74±0.32) respectively. From the above observations, it is 
concluded that F11 formulation gives maximum drug release 
within 10 min (fig. 6). 
The drug release for the formulations F12, F13, and F14 are at 60 
min (20.40±0.09), 60 min (22.12±0.41), 60 min (25±0.43) 
respectively. From the above observations, it is concluded that F14 
formulation gives maximum drug release (Fig.7). The release of the 
drug rate was delayed when compared with other super disintegrant 
formulations [9, 11]. 
 
Fig. 6: In vitro release studies of prepared tablets at different 
concentrations of Croscarmellose sodium (n=3,mean±SD) 
 
 
Fig. 7: In vitro release studies of prepared tablets at different 
concentrations of L-HPC (n=3, mean±SD) 
 
In vitro dissolution studies showed that the comparison of drug 
released rate from the F3, F6, F11and F14 formulations within 10 
min. The F3 formulation containing crospovidone in the 
concentration of 15 % showed minimum disintegration time of 82.6 
s, wetting time of 86 s and 23.3 % drug and 33.04% drug was 
released within 5 and 60 min respectively. The F6 formulation 
containing sodium starch glycolate in the concentration of 15 % 
showed minimum disintegration time of 23.5 s, wetting time of 29.5 
s and 48.3 % drug, 53.1 % and 56.04 % drug was released within 
5,10 and 60 min respectively. 
The F11 formulation containing croscarmellose sodium in a 
concentration of 25 % showed minimum disintegration time of 12.8 
s, wetting time of 19.8 s and 73.4 % drug, 84.7 %and 87.4 % drug 
was released within 5,10 and 60 min respectively. The F14 
formulation containing L-HPC in the concentration of 15 % showed 
minimum disintegration time of 142 seconds, wetting time of 147.6 s 
and 17.8 % drug, 22.8 % and 25 % drug was released within 5,10 
and 60 min respectively. The optimized formulation of F11 was 
compared with F3, F6, F14 and the dissolution parameters of three 
formulations are shown in and fig. 8. 
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Fig. 8: In vitro drug release studies on prepared tablets, 
comparison of F3, F6, F11 and F14 formulations (n=3, 
mean±SD) 
 
In vitro dissolution studies showed that more than 50 % of the drug 
was released from the F6, F9, F10, F11 formulations within 5 min. 
The F11 formulation containing croscarmellose sodium in a 
concentration of 25 % showed minimum disintegration time of 12 s, 
wetting time of 19.80 s and 73 % drug and 84.7 % drug was released 
within 5 and 10 min respectively.  
The optimized formulation of F11 was compared with the Pure drug 
(Plain powder), a tablet without super disintegrant (DCT) and the 
dissolution parameters of three formulations are shown in fig. 9. 
 
 
Fig. 9: In vitro drug release studies on prepared tablets, 
comparison of pure drug, DCT and F11 formulations (n=3, 
mean±SD) 
 
In vivo disintegration time 
Considering wetting time, water absorption ratio, in vitro 
disintegrating time, and cumulative % drug released, formulations 
containing CCS were considered to be better than those containing 
SSG, CP and L-HPC. F11 (CCS 25%) was considered as the optimal 
FDT formulation among all of the 14 formulations tested in this 
study and selected for in vivo disintegration studies. The test was 
performed as discussed in an earlier section [21,24]. 
The disintegration time of FDTs containing F11 (CCS 25%) was 
measured in the mouths of six healthy male human volunteers as per 
the protocol. Complete disintegration was achieved at 13.1, 13, 14.6, 
16.1, 13.1, and 15.6 s, respectively (mean±SD, 14.25 and 0.79 s). The 
same formulation was administered thrice to each individual, and 
the average of triplicate measurements represents an individual oral 
disintegrating time. The Results were depicted in Table. 3. Based on 
these data, this in vivo study demonstrates the applicability of the 
formulated FDT for potential commercial use. 
 
Table: 3 In vivo disintegrating time for optimized formulation 
(n=3, mean±SD) 








In vivo pharmacodynamic studies 
The blood glucose levels were determined by using blood glucose 
test stips (Gluco chek) with a glucometer. Blood samples were 
collected at predetermined intervals, i.e. 15 min, 30 min, 45 min, 60 
min, 2 h, 4h, 6 h, 8 h, 12 h, 24 h. The results are shown in the fig. 7. 
Blood glucose levels were reduced considerably in the group II and 
group III rats treated with DCT (without super disintegrant) and 
pure drug within 4 h is up to 60 %. The reduction in blood glucose 
levels was significant in group IV rats treated with optimized FDT 
formulation. Blood glucose levels were decreased in 2 h (Fig.10). The 
rapid decrease of blood glucose levels in group IV rats might be due 
to the rapid absorption of the drug and rapid onset of action from 




Fig. 10: Percentage of blood glucose level decrease in diabetes 
induced rats on oral administration of the pure drug, FDT 
powder, DCT powder (Without superdisintegrants tablet). (n=3, 
mean±SD) 
 
Fourier transforms infrared spectroscopy 
The characteristic FTIR spectra of Glimepiride, Croscarmellose 
sodium, Physical mixture, Tablet were shown in Fig.8. The 
stabilizing interaction between the OH-group of glimepiride 
(Hydrogen bonded at ~ 3367 cm-1) and C-H stretch in the alkanes 
(2929 cm-1) and C=C stretch in the alkenes (1674 cm-1) and NO2 
symmetrical stretch group of nitro compound (1346 cm-1) were 
found to remain unchanged in all of the Croscarmellose sodium, 
Physical mixture, tablet.  
Croscarmellose sodium showed peaks at OH-stretch (Hydrogen 
bonded at ~ 3566 cm-1) and C-H stretch in the alkanes (2920 cm-1) 
and C=C stretch in the alkenes (1670 cm-1) and NO2 symmetrical 
stretch group of nitro compound (1375 cm-1). Physical mixture 
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showed peaks at OH-stretch (Hydrogen bonded at ~ 3369 cm-1) and 
C-H stretch in the alkanes (2922 cm-1) and C=C stretch in the alkenes 
(1674 cm-1) and NO2 symmetrical stretch group of nitro compound 
(1346 cm-1). Tablet showed peaks at OH-stretch (Hydrogen bonded 
at ~ 3367 cm-1) and C-H stretch in the alkanes (2916 cm-1) and C=C 
stretch in the alkenes (1674 cm-1) and NO2 symmetrical stretch 
group of nitro compound (1373 cm-1). 
In the optimized formulations, the presence of all the characteristic 
peaks of the Glimepiride indicates a lack of any strong interaction 
between the drug and the excipients. 
CONCLUSION 
From the experimental results, it can be concluded that the fast 
dissolving system can be formulated using different super 
disintegrants like Sodium Starch Glycolate, Crospovidone, 
Croscarmellose Sodium and L-HPC by Direct Compression 
technique. The FTIR Spectra revealed that Croscarmellose Sodium 
and excipients used were compatible with the drug. The formulated 
tablets showed compliance for various physiochemical parameters 
viz. hardness, friability, weight variation, content uniformity and 
disintegration and dynamic studies. The drug content was within an 
acceptable range which ensured dose uniformity in the formulation. 
The in vitro studies revealed that formulation F11 showed maximum 
drug release and drug content. The water absorption ratio revealed 
that Formulation F11 showed best wetting time results. On the basis 
of release drug disintegration and wetting studies, it can be 
concluded that the formulation F11 is the optimum formulation. In 
vivo pharmacodynamic study demonstrated that there is a decrease 
in blood glucose levels in diabetes-induced rats within 2 h and 
showed good dynamic activity. From the above-obtained data it 
concluded that fast disintegrating tablets of glimipiride are better 
formulations to treat diabetes. 
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